BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Spikevax (elasomeran) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Spikevax (elasomeran)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07863635-10899@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Spikevax (elasomeran): Phase 4 readout est. (NCT07863635)
DESCRIPTION:Spikevax (elasomeran)\, phase 4\, COVID-19.\nStudy: A Study to 
 Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-contain
 ing Formulations\nEstimated primary completion: 11 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/elasomeran#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07863635
URL:https://assetmemo.bio/drug/elasomeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585241-10899@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Spikevax (elasomeran): Phase 4 readout est. (NCT06585241)
DESCRIPTION:Spikevax (elasomeran)\, phase 4\, COVID-19.\nStudy: A Study to 
 Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-contain
 ing Vaccine Formulations\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/elasomeran#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06585241
URL:https://assetmemo.bio/drug/elasomeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266558-10899@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Spikevax (elasomeran): Phase 4 readout est. (NCT07266558)
DESCRIPTION:Spikevax (elasomeran)\, phase 4\, COVID-19.\nStudy: A Study to 
 Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participant
 s 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronaviru
 s Disease 2019 (COVID-19)\nEstimated primary completion: 16 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/elasomeran#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07266558
URL:https://assetmemo.bio/drug/elasomeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
